Navigation Links
Study reveals no impact of age on outcome in chronic myeloid leukemia patients treated with imatinib
Date:3/30/2011

(WASHINGTON, March 30, 2011) While the median age at diagnosis for chronic myeloid leukemia (CML) is over 60 years old and incidence increases dramatically with age,limited data are available about the long-term outcome for older patients treated with imatinib, the standard first-line therapy used to treat CML. Results from a study published today in Blood, the Journal of the American Society of Hematology, reveal that age does not affect response to imatinib and study investigators conclude that overall survival for CML is similar in older and younger patients treated with the drug.

Two widely used prognostic scores for CML, the Sokal and EURO risk scores, have historically identified older age as a predicting factor of lower response rate and poorer outcome. However, these risk scores were validated before imatinib was introduced as a therapy for CML and may now hold less relevance, as imatinib has dramatically improved the prognosis for CML patients.

"Older age has typically been considered a poor prognostic factor in patients with CML and has a negative impact on response rates and long-term survival, regardless of treatment," said Gabriele Gugliotta, MD, co-author of the study and Fellow in the Department of Hematology and Oncology at St. Orsola-Malpighi Hospital at the University of Bologna in Bologna, Italy. "Our study focused on disease progression, treatment response, and survival of this specific patient population to assess the role of imatinib in older patients."

To test whether age at diagnosis is a valid predictor of response, researchers from several institutions in Italy conducted an analysis of 559 patients with early chronic phase CML (six months or less from diagnosis to start of imatinib treatment) who were enrolled in three concurrent clinical trials in the Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party, between May 2003 and April 2007. Trial participants over age 65 were defined as "older" patients and those under age 65 were classified as "younger" patients.

Results from the patient analysis revealed that complete hematologic response, or a return to normal blood cell and platelet counts, was observed at three-month follow-up in 97 percent of the older age group and 96 percent of the younger age group. At six, 12, and 24 months follow-up, 69 percent, 78 percent, and 74 percent of older patients and 67 percent, 77 percent, and 78 percent of younger patients, respectively, achieved complete cytogenetic response, or the point when no leukemic cells are detected in the blood. As for long-term survival, after discounting deaths unrelated to CML in both the older and younger patients, researchers found no significant difference in mortality rates between the two age groups. The adjusted overall survival rate for the older patients was 94 percent, compared to 96 percent for the younger patients (p=0.4), further demonstrating that age was not a significant factor in imatinib response and did not affect patient survival.

"This is the first study that has specifically analyzed the long-term outcome of older patients with early chronic phase CML treated with imatinib," said Gianantonio Rosti, MD, lead study author and hematologist in the Department of Hematology and Oncology at St. Orsola-Malpighi Hospital at the University of Bologna. "While increasing age is generally associated with higher mortality, the results of our analysis demonstrate that when it comes to treating CML patients, older age must not be a limitation for treatment with imatinib, as it is a very effective therapy for this patient population."


'/>"/>

Contact: Lindsey Love
webmaster@hematology.org
202-552-4925
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. Case study reports singing lowers patients blood pressure prior to surgery
2. Study finds surprising gender differences related to sexual harassment
3. Parkinsons Drugs Linked to Behavior Problems in Study
4. Conflicts of Interest Cloud Heart Treatment Guidelines: Study
5. Negative attitudes toward fat bodies going global, study finds
6. Airport Scanners Appear Safe, Study Finds
7. Surgeon Enthusiasm May Spur Higher Rates of Back Pain Procedures: Study
8. Teens Who Smoke Early Often Try Pot Later, Study Finds
9. Study finds changes in incidence of end-stage renal disease from lupus nephritis
10. Some women worry too much about breast cancer returning, U-M study finds
11. Laughter, Music May Lower Blood Pressure, Study Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
Breaking Medicine Technology: